

REVIEW

## The role of telomeres and telomerase reverse transcriptase isoforms in pluripotency induction and maintenance

Jonathan H. Teichroeb<sup>a</sup>, Joohwan Kim<sup>a</sup>, and Dean H. Betts<sup>a,b</sup>

<sup>a</sup>Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada;

<sup>b</sup>Children's Health Research Institute, Lawson Health Research Institute, London, Ontario, Canada

### ABSTRACT

Telomeres are linear guanine-rich DNA structures at the ends of chromosomes. The length of telomeric DNA is actively regulated by a number of mechanisms in highly proliferative cells such as germ cells, cancer cells, and pluripotent stem cells. Telomeric DNA is synthesized by way of the ribonucleoprotein called telomerase containing a reverse transcriptase (TERT) subunit and RNA component (*TERC*). TERT is highly conserved across species and ubiquitously present in their respective pluripotent cells. Recent studies have uncovered intricate associations between telomeres and the self-renewal and differentiation properties of pluripotent stem cells. Interestingly, the past decade's work indicates that the TERT subunit also has the capacity to modulate mitochondrial function, to remodel chromatin structure, and to participate in key signaling pathways such as the Wnt/ $\beta$ -catenin pathway. Many of these non-canonical functions do not require TERT's catalytic activity, which hints at possible functions for the extensive number of alternatively spliced TERT isoforms that are highly expressed in pluripotent stem cells. In this review, some of the established and potential routes of pluripotency induction and maintenance are highlighted from the perspectives of telomere maintenance, known TERT isoform functions and their complex regulation.

### ARTICLE HISTORY

Received 6 July 2015  
Revised 12 November 2015  
Accepted 15 December 2015

### KEYWORDS

Alternative splicing;  
embryonic stem cells; hESC;  
iPSC; pluripotency;  
telomerase; telomere; TERT

### Background

The evolution of linearly organized DNA and inability of DNA polymerases to conserve the chromosomal ends have necessitated the need for non-coding telomeric DNA to cap the chromosomes.<sup>1–3</sup> These repeating DNA sequences protect an individual's chromosomes from fusion and erosion of coding DNA. Continued shortening of telomeric DNA due to the end-replication-problem eventually leads to critically short telomeres that induce senescence to avoid chromosomal damage.<sup>3</sup> This effect, known as the Hayflick limit<sup>4,5</sup> defines the number of possible cellular replications before cells senesce, and thus limits cellular lifespan. On an organismal scale, short telomere syndromes exhibit strong correlations with certain pathologies, such as pulmonary fibrosis,<sup>6,7</sup> arteriosclerosis,<sup>8</sup> aplastic anemia,<sup>6,9</sup> chronic liver disease,<sup>10</sup> and intrauterine growth restriction (IUGR) due to trophoblast stem cell dysfunction.<sup>11–13</sup>

Landmark work published by Carol Greider and Elizabeth Blackburn<sup>14</sup> uncovered the telomerase protein complex needed to re-lengthen telomeric DNA and maintain proliferation of a species and its germ cells. At the core of this ribonucleoprotein complex, the telomerase reverse transcriptase (TERT) protein in conjunction with its telomerase RNA component (*TERC*) is sufficient to extend telomeric sequences *in vitro*.<sup>15</sup> Elevated expression of TERT is found in over 90% of cancers in order to maintain proliferation, and much effort has been made in unveiling the pathogenic role of TERT in the diseased state (as previously reviewed<sup>16,17</sup>). However, high TERT levels naturally

arise in non-pathogenic settings such as in the germline and stem cells, and in particular embryonic stem cells (ESCs). Prolonged proliferative capacity of ESCs is achieved by the maintenance/re-lengthening of telomere length via high telomerase activity. As such, human (h)ESCs are capable of being passaged over 120 times with no decrease in telomerase activity, telomere length and pluripotency potential.<sup>18</sup>

Several recent reviews<sup>19–21</sup> have highlighted different mechanisms by which telomeres and TERT are affected by pluripotency. These discussions tend to be singularly focused with pluripotency acting as an effector. Canonically, any feedback from TERT to pluripotency occurs only indirectly through telomere-mediated effects such as DNA damage responses (DDR). It is well established that telomere length (in particular critically short telomeres), as maintained through the canonical function of TERT, affects pluripotency<sup>22</sup> and embryonic viability.<sup>23</sup> However, the past decade's work on TERT has revealed non-canonical, extra-telomeric functions of TERT, much of whose functional significance are yet to be elucidated in the context of stem cell biology. It is quite possible that many of the non-canonical pathway functions of TERT do affect pluripotency and stem cell maintenance. Recent studies<sup>24,25</sup> have uncovered novel non-canonical functionality in some of the TERT isoforms that may also impact stem cell function. This review will discuss the multiple known and speculative connections to pluripotency induction and maintenance in the context of telomeres length, TERT isoforms, and their canonical and non-canonical functions.

## Telomeres and pluripotent stem cells

Telomere length is a basic requirement for sustaining the replicative potential of somatic cells and its maintenance allows for unlimited self-renewal of stem cells.<sup>18,26</sup> Both murine and human embryonic stem cells demonstrate robust telomerase expression for extended population doublings and are capable of maintaining long telomeres.<sup>27,28</sup> Similarly, human and murine induced pluripotent stem cells (iPSCs) are capable of carrying out re-elongation of telomeres in at least some clones, although the telomere length and activity characteristics appear to be clonally unique.<sup>28-33</sup> Conversely, the process of differentiation triggers down-regulation of telomerase and initiates telomeric attrition.<sup>34,35</sup> Following the extended cellular division required to form adult tissues, terminally differentiated cell types typically exhibit low or undetectable levels of telomerase activity and shortened telomeres.<sup>36,37</sup> While extensive species similarities in the regulation of TERT and telomeres exist, **Table 1** highlights some significant differences that will be highlighted in subsequent sections.

Both the increase and attrition of telomere length occurs gradually during S-phase<sup>38</sup> and requires multiple cell divisions. On the other hand, the initial stage of iPSC reprogramming is a fairly rapid process, and therefore telomere-mediated effects may not arise in the midst of reprogramming. Not surprisingly, the age of human cell donor has little effect on the ability to reprogram the cells to a pluripotent state.<sup>30,39</sup> In fact, human iPSCs (hiPSC) derived from cells with telomerase activity defects and non-critically short telomeres still can be reprogrammed to a pluripotent state.<sup>29,40</sup> This suggests that, while critically short telomeres significantly impact reprogramming efficiency, increasing telomere length far beyond the length

needed to support initial proliferation requirements does not confer additional reprogramming advantage. This point is often masked by the use of mean telomere length, which generally has correlation with effects such as lifespan and pluripotency near short lengths where the telomere length distribution skewness is changing significantly.<sup>41</sup> However, following reprogramming mis-localization of human TERT (hTERT), and all abnormalities leading to similar telomere attrition result in eventual loss of self-renewal and pluripotency.<sup>42</sup> Similarly, long term self-renewal and teratoma formation in murine and porcine iPSCs with short telomeres are generally impaired.<sup>31,43</sup> In addition, PSCs with short telomeres in a variety of species display mitochondrial dysfunction,<sup>44</sup> uncapping events, and reduction in H3K27me3 distal to telomeres including global hypomethylation which contributes to reactivation of pluripotency genes,<sup>45</sup> and possibly reprogramming transgenes.<sup>31,33,46</sup>

Partially reprogrammed iPSCs often show little TERT activation and short telomeres.<sup>32</sup> This reprogramming failure is likely the reason for the failure of the TERT promoter to be activated. Conversely, it is unlikely that lack of TERT activation causes partial reprogramming as TERT expression and/or activity does not guarantee pluripotency.<sup>28,35,47,48</sup> However, telomere length is touted as a biomarker of reprogramming, with hiPSC telomere lengths plateauing close to the hESC telomere length of about 12 kbp despite continued high telomerase expression.<sup>49</sup> Such stabilization of telomere length, in addition to proper downregulation of hTERT following differentiation, is a strong hallmark of non-transformed human pluripotent stem cells.<sup>30,35,49</sup> hESCs and hiPSCs normally suppress the ALT (alternative lengthening of telomerase) pathway<sup>49</sup> and, in the absence of hTERT, short telomeres typically lead to up-

**Table 1.** Species-specific comparison of telomere/telomerase effects and their interactions with pluripotency regulation.

		Organism		
		homo sapiens	murine	porcine
<b>Telomere Length</b>	<b>Inner cell mass</b>	12 kb <sup>162</sup>	86 kb in-vivo 50 kb in-vitro <sup>52</sup>	
	<b>ESCs</b>	12 kb <sup>49</sup>	144 kb at p12 <sup>52</sup>	33.0 <sup>46</sup>
	<b>iPSCs</b>	Similar to ES <sup>49</sup>	similar to ES <sup>53</sup>	up to 31.5kb <sup>31</sup>
<b>Effect on ES/iPSC pluripotency</b>	<b>TERT knockdown*</b>	No <sup>86</sup> /Yes <sup>84,85</sup>	No <sup>45,124</sup> /Reprogramming effects <sup>63</sup>	unknown
	<b>TERC knockdown*</b>	No <sup>40,85</sup>	No major effect <sup>51</sup> /mitochondria <sup>44</sup> , naivety <sup>33</sup>	unknown
<b>TERT Null Phenotype</b>	<b>TERT -/-*</b>	unknown/unknown	None <sup>76,83,123</sup> , /WNT-defect <sup>105</sup>	unknown
	<b>TERC -/-*</b>	unknown/unknown	None <sup>77</sup>	unknown
<b>iPSC Reprogramming</b>	<b>Telomeres re-lengthen</b>	Yes-sporadic <sup>28</sup>	Yes-sporadic <sup>32</sup>	Yes-sporadic <sup>31</sup>
	<b>Elongation period</b>	up to passage 15 <sup>49</sup>	continuous <sup>52</sup>	unknown
	<b>ALT pathway</b>	suppressed <sup>49</sup>	active <sup>46</sup>	active <sup>31</sup>
<b>iPSC TERT increase</b>		> 100x <sup>32</sup>	approx. 3x <sup>32</sup>	
<b>Knockdown SUV39h1 and SUV39h2<sup>46</sup></b>		Telomere shortening	Telomere elongation	Telomere elongation
<b>Non-telomere Interactions</b>	<b>NF-kB (RelA/p65)<sup>111,163</sup></b>	Stabilizes p65 and its Nuclear Residency	mTERT -/- and mTERT -/- defective NF-kB signaling	
	<b>BRG1<sup>111,105</sup></b>	IL-6,8 & TNF-α promoter binding		
	<b>RNA species<sup>102,107</sup></b>	BRG1/GNL3	BRG1	
	<b>Mitochondrial membrane proteins<sup>158</sup></b>	RMRP		
	<b>mtDNA<sup>158</sup></b>	LINE1/alphoid ssRNA		
		TOM20/TOM40 & TIM23		
		ND1 & ND2 mtDNA		

Categories with mixed results are indicated with supporting references.

\*in absence of short telomere effects.

regulation of the p53-mediated apoptosis pathway, or chromosomal rearrangements.<sup>29</sup> Thus, the aforementioned telomere maintenance characteristics in pluripotency are not preserved across vertebrates (Table 1).


Instead of using murine TERT (mTERT), initial lengthening of murine telomeres during early embryo cleavage<sup>50</sup> is largely achieved through alternative lengthening of telomerase (ALT) pathways. To a lesser extent, mESCs and miPSCs also appear to upregulate and utilize ALT mechanisms for telomere maintenance intermittently.<sup>33,51</sup> mESCs and miPSCs also do not exhibit the *in vitro* plateau in telomere length that is characteristic of hESCs/hiPSCs.<sup>52</sup> While NT-mESCs generally have completed telomere lengthening and full reprogramming by the blastocyst stage,<sup>44</sup> miPSCs may take up to 30 passages to achieve mESC lengths<sup>53</sup> and only do so sporadically.<sup>32</sup> Control of telomere length is an intricate process involving many factors. As previously reviewed,<sup>19</sup> mESCs and miPSCs control telomere length largely by modulating telomeric epigenetics and regulation by several proteins, including ZSCAN4,<sup>51,54-56</sup> ATRX,<sup>54,55</sup> RIF1,<sup>56</sup> TRF1<sup>52,57</sup> TPP1 and other shelterin complex components.<sup>52,58</sup> Increased telomere length, as part of the establishment of the pluripotent epigenome, occurs only after multiple passages, and is accomplished through epigenetic modifications of histones and subtelomeric DNA methylation.<sup>33,59</sup> During cellular reprogramming, hiPSC sub-telomeres become hyper-methylated with both *de novo* methylation and pockets of demethylation occurring.<sup>34</sup> At the same time, histone H3.3 plays a critical role in regulating telomeric chromatin accessibility.<sup>60</sup> Whereas during differentiation H3.3 is decreased causing telomeres and subtelomeres to take on a

more heterochromatic state, complete knockdown of H3.3 leads to telomeric dysfunction.<sup>60</sup> Early lengthening of telomeres, within the first few passages following reprogramming, is preceded by a significant reduction of H3K9/H4K20 trimethylation.<sup>49</sup> However, this must be followed by reestablishment of H3K9/H4K20 me3 repressive marks to stabilize telomeric length.<sup>49</sup>

While knockdown of histone methyltransferases (HMTs) SUV39h1 and SUV39h2 in mice and pigs leads to increased telomere length, decreased demethylases DNMT1/3a/3b and decreased H3K9me3 marks,<sup>46</sup> knockdown in human cells leads to telomere length shortening.<sup>46</sup> This disparity is likely due to species differences (Table 1) that repress ALT pathways in humans, but not murine or porcine cells.<sup>31,46</sup> Consequently, although heterozygous mTERC-/+ miPSCs and to a lesser extent mTERC-/- miPSCs are capable of maintaining pluripotency and telomere length in mice, possibly due to the activation of the ALT pathway,<sup>33</sup> hTERT-/+ hiPSCs show poor telomere elongation, and DKC1 (Dyskerin - a telomerase complex component) hiPSC mutants (TERC deficient) do not elongate telomeres.<sup>42</sup>

### Pluripotency and canonical TERT functions

As discussed above, telomeres have strong feedback mechanisms to regulate pluripotency. TERT is the catalytic component of telomerase whose function, when combined with TERC, is to maintain telomere length and structure. This section will establish the canonical pluripotency-to-TERT links



**Figure 1.** Proposed routes of pluripotency maintenance and self-renewal by pluripotent stem cells through functions of telomerase reverse transcriptase (TERT) isoforms. TERT expression is regulated by a number of key pluripotency/transcription factors. Conversely, TERT regulates pluripotency and self-renewal via canonical (telomeric) and non-canonical (mitochondrial, transcriptional) functions in pluripotent stem cells (PSCs). Telomere- and chromosome-mediated TERT effects lead to changes in pluripotency and cell proliferation by modulating the activities of transcription factors (c-Myc,  $\beta$ -Catenin, NF- $\kappa$ B, p53). This figure would be much more complex with additional TERT variant specific functions, as well as multiple TERT splice variants modulating each of its current roles. Common acronyms: mtDNA (mitochondrial DNA),  $\Delta\psi/m$  (Mitochondrial Membrane Potential/MMP), ROS (Reactive Oxygen Species) UCP2 (Mitochondria uncoupling protein 2),  $\beta$ -Cat ( $\beta$ -Catenin/CTNNB1), DDR (DNA Damage Response). The line without arrowhead underneath p53 indicates existing evidence for interaction with lack of mechanistic understanding.

that will be contrasted with the subsequent non-canonical TERT section (below). Putative links are highlighted in Fig. 1.

During embryogenesis and induced pluripotent stem cell (iPSC) generation, TERT and other telomerase components are upregulated, and remain so in self-renewing PSCs. TERT activation is a beneficial event for lengthening telomeres in order to stabilize them and suppressing the DNA damage response (DDR) prior to other epigenetic changes requiring extensive proliferation. Telomerase activity may thus be useful in assessing iPSC reprogramming efficiency and as a hallmark of non-transformed somatic cells, which should contain low telomerase expression and activity.<sup>61</sup> Moreover, upregulation of pluripotency genes is strongly connected with expression of TERT, the overexpression of which enhances reprogramming efficiency.<sup>62,63</sup> For example, porcine iPSCs can only maintain telomeres with continued expression of exogenous reprogramming factors to maintain TERT levels,<sup>31</sup> and partially reprogrammed mouse embryonic fibroblasts (MEFs), and porcine embryonic fibroblasts (PEFs) show little *TERT* promoter activation and poor telomere elongation. However, while low telomerase activity is correlated with partial reprogramming, high levels of TERT alone does not induce a pluripotent state,<sup>48</sup> nor does pluripotency strictly require high levels of TERT.<sup>28</sup> The transcriptional control by which TERT is upregulated during reprogramming to a pluripotent state has only recently begun to be elucidated.

During reprogramming, endogenous TERT up-regulation is a late event<sup>64</sup> that precedes endogenous upregulation of OCT4, SOX2<sup>33</sup> and *TERC* (whose promoter is bound by OCT3/4 and NANOG<sup>40</sup>). TERT up-regulation is instead simultaneous with the overexpression of KLF4.<sup>33</sup> Recently, KLF4 binding has been mapped directly to the *TERT* proximal promoter where KLF4 is able to upregulate TERT when  $\beta$ -catenin acts as a cofactor.<sup>49,65,66</sup> This appears to be a key function of KLF4, as hTERT overexpression is capable of rescuing KLF4 knockdown-triggered cellular differentiation.<sup>66</sup> Furthermore, KLF4- $\beta$ -catenin in complex with TCF-4 or TCF-1 serves either to activate or to repress TERT, respectively.<sup>65,67</sup> This interplay helps to provide a mechanism by which pluripotent and cancer stem cells are able to upregulate TERT to initiate cellular immortalization through telomere maintenance. Additionally, cell lines containing short telomeres are quite refractory to reprogramming and this inhibition is mediated by the p53 apoptosis/senescence pathway, which when removed allows the reprogramming of cell lines with critically short telomeres (albeit resulting in widespread chromosomal aberrations).<sup>68</sup> Hence, TERT upregulation through KLF4 may serve as an additional indirect means by which the p53 pathway can be suppressed via telomere maintenance during reprogramming.<sup>69</sup>

C-MYC (one of the original Yamanaka factors<sup>70</sup>) remains a common, albeit dispensable, cofactor during iPSC reprogramming,<sup>71</sup> and maintains high expression following transformation to a pluripotent state. C-MYC binds to and activates the *TERT* promoter.<sup>65,72,73</sup> Indirect evidence of C-MYC's importance is provided by the knockdown of SIRT1 which represses C-MYC, and accompanies a reduction in mTERT levels.<sup>47</sup> However, C-MYC is not required for reprogramming and its expression level is generally not correlated with TERT levels

post-reprogramming, raising the question of whether C-MYC actually plays a major role in maintaining TERT expression.<sup>32,33,53</sup> It is possible that this effect is still mediated through KLF4 as SIRT1 also affects NANOG expression, which, in turn can regulate KLF4 and C-MYC through feedback loops with other pluripotency factors (for example OCT3/4 and mir145).<sup>74,75</sup> C-MYC may have a more important role in hiPSC generation where ALT does not contribute to the initial elongation of telomeres, and thus hTERT must play a more substantial role.

While non-canonical extra-telomeric functions of TERT are becoming apparent (*see* following section), it appears that, at least in the murine context, it is the canonical telomeric maintenance that has the greatest effect *in vitro*.<sup>76,77</sup> In agreement with this, complete abolition of telomerase function through mTERT<sup>76</sup> or *mTERC*<sup>77</sup> knockout in mice does not result in gross pathological symptoms for 6 to 8 generations at which point telomeres are critically shortened. Moreover, haplosufficient *mTERC*+/- mESCs can contribute to tetraploid embryos, whereas full-knockout *mTERC*-/- cells are unable to contribute despite containing unmodified mTERT.<sup>78</sup> Collectively, it can be deduced that TERT and canonical telomerase activity is dispensable during the reprogramming process of murine cell lines with sufficient telomere length,<sup>33</sup> but ultimately telomere maintenance is a required feature of prolonged self-renewal. In support of this, knockdown of ZSCAN4, an enhancer of chromosome stability and telomere-sister chromatid exchange (T-SCE)<sup>51</sup> initiates cell crisis and apoptosis within 8 passages in mESCs, whereas *mTERC*-/- cells upregulate ZSCAN4 possibly to compensate and are subsequently sustainable for up to 450 population doublings.<sup>51</sup>

Similarly, mTERT appears to be dispensable for the *in vitro* differentiation of mESCs with sufficient telomere length.<sup>45</sup> In a study by Pucci *et al.*, mTERT -/- mESCs with both short and long telomeres appear to differentiate normally upon LIF withdrawal.<sup>45</sup> However, differentiated cells derived from short telomere mESCs do not maintain their non-pluripotent status and begin to re-express NANOG<sup>45</sup> through unknown mechanisms. Prior to differentiation NANOG is also expressed at high levels in mTERT -/- mESCs with short telomeres.<sup>44</sup> Additionally, Pucci *et al.* found that ESRRB, a KLF4 substitute during reprogramming<sup>79</sup> and a direct target of NANOG,<sup>80</sup> is also strongly upregulated.<sup>45</sup> Previous studies have demonstrated p53 binding to the promoters of NANOG and ESRRB<sup>81</sup> and its ability to either enhance or repress the pluripotency genes.<sup>80</sup> Thus, p53 signaling in response to short telomeres of mTERT -/- mESCs may act to upregulate NANOG. Alternatively, NANOG up-regulation could be an incidental effect of DNA methyl transferase (DNMT) down-regulation leading to hypo-methylation in an attempt to upregulate the ALT pathway as previously proposed.<sup>58</sup> Another possibility is that the short telomeres might have led to destabilization of shelterin complexes and the resultant release of RAP1. RAP1 can modulate the steady state level of E-cadherin and consequently OCT3/4 and NANOG.<sup>82</sup> Lastly, as DKC1 regulates promoters of pluripotency genes, it is possible that removal of TERT from the telomerase complex disrupts the holoenzyme allowing DKC1 to more efficiently modulate pluripotency promoters.<sup>83</sup> Further investigation of mechanisms of telomeric induced deregulation of pluripotency

genes during differentiation should yield important information as to how short telomeres influence distal genes.

Little work has been carried out with the knockout/knockdown of telomerase subunits in human cells. Of the studies that have been carried out, conflicting results have emerged. Yang *et al.*<sup>84</sup> suggest that lentiviral knockdown of hTERT in hESCs results in their spontaneous differentiation and the inability to generate a stable ES cell line. In partial agreement, chemical inhibition of hTERT activity in hESCs leads to lowered pluripotency and increased differentiation, while curiously, similar blocking of telomerase activity through *TERC* steric inhibition has no effect suggesting an extra-telomeric role for TERT in maintaining self-renewal in the undifferentiated state.<sup>85</sup> In contrast, Sexton *et al.* did not observe any reduction in pluripotency (as measured by sustained OCT3/4 expression only) after establishing stable hESC lines through zinc finger-mediated knockout of hTERT.<sup>86</sup> However, Sexton *et al.* do observe a loss of self-renewal and differentiation beginning around 75 days post TERT-knockout, when the cells reach a critical telomere length of 2–3kb. These drastic differences likely arise from effects of the modalities used to knockout/knockdown hTERT or alternatively from telomeric differences in the cell lines used. Despite this, as discussed in the previous section (also see Table 1), humans do not normally have a substantial ALT pathway contribution and other species-specific differences exist. For example, mTERT expression is only upregulated at low (3 fold) levels during reprogramming as compared to hTERT in hiPSCs (several hundred fold), despite high promoter activation that correlates with reprogramming stage.<sup>32</sup> *TERC* is typically expressed in excess, even in differentiated tissues,<sup>58</sup> and thus may not be a limiting factor in *mTERC* +/- murine cells. Lastly, as laboratory mice are known to have extremely long telomeres and short lifespans, telomeric effects may be delayed compared to humans.

### Non-canonical functions of telomerase and pluripotency

In recent years, the discovery of telomere-independent effects of TERT on proliferation<sup>87-95</sup> and perturbations of resistance to reactive oxygen species damage<sup>96-100</sup> have led to a burgeoning body of evidence that indicates that TERT has many functions outside its canonical role in telomere length maintenance.<sup>101</sup> Some of these extra-telomeric effects include acting as an RNA-dependent RNA polymerase,<sup>102</sup> a mitochondrial reverse transcriptase,<sup>103</sup> interacting with nucleostemin (GNL3),<sup>104</sup> WNT, BRG1,  $\beta$ -catenin,<sup>87,105</sup> NF- $\kappa$ B,<sup>106</sup> and modulating endogenous siRNA<sup>102,107</sup> and miRNA profiles.<sup>108</sup> Although the non-canonical effects have been observed mainly in non-pluripotent cell types, many of the affected pathways play key roles in pluripotency. This section will discuss extra-telomeric roles and possible direct or indirect connections to pathways also involved in the self-renewal and maintenance of stem cells. Some of these confirmed and speculative pathways are summarized in Fig. 1.

#### TERT, BRG1 and Wnt

A number of effects point to TERT (with or without *TERC*) possessing non-canonical functions. TERT is capable of aiding the maintenance of self-renewal in human limbal and

mesenchymal stem cells, increasing the efficiency of directed differentiation,<sup>48,99</sup> enhancing iPSC reprogramming efficiency<sup>40</sup> and activating resting hair follicle stem cells.<sup>90</sup> Several recent reports have shown that TERT is able to interact with BRG1 in a WNT/ $\beta$ -catenin dependent manner. The canonical WNT pathway is extensively involved in differentiation of cell lineages and BRG1 loss of function is embryonic lethal and a critical developmental transcription factor.<sup>109-113</sup> Despite demonstrating TERT-BRG1 interaction in both murine cellular and tissue ChIP assays,<sup>105</sup> and the TERT-BRG1-GNL3 complex in specific human cell lines,<sup>107</sup> the widespread applicability of TERT-BRG1 interactions has been called into question.<sup>114</sup> Of 4 cell lines investigated, Listerman *et al.* could not show a consistent interaction,<sup>114</sup> and other studies have not found BRG1 interactions.<sup>106,115</sup> However, supportive evidence has been offered in several other studies.<sup>105,107,108</sup> MicroRNA (miRNA) expression alterations during the suppression of TERT in THP-1 and HeLa cells are strikingly similar to microRNA changes during BRG1 suppression.<sup>108</sup> Though mostly inferred from correlative data, it is likely that these changes are mediated through TERT's interaction with transcriptional factors BRG1, GNL3 and NF- $\kappa$ B that regulate miRNAs and not by direct miRNA interaction.<sup>108</sup> Additionally, axis formation defects following TERT knockdown in *Xenopus* are consistent with a role for TERT in the Wnt pathway.<sup>105</sup> In contrast, in human cells, association of GNL3 with TERT-BRG1 produce RNA dependent RNA polymerase activity (RdRP), forming siRNA targeted to regulate centromeric alphoid domains, and non-centromeric LINE1 elements, thereby modulating heterochromatin during mitosis.<sup>107</sup> Thus, TERT-BRG1 may play varying roles depending on which cofactors are present, and these associations if present during pluripotency and differentiation would directly link TERT to a developmental role.

Unfortunately, despite *in vitro* evidence for TERT-BRG1 interactions, *in vivo* defects observed in *TERT*-null mice (with sufficient telomeres) have only been seen in a single mouse strain by one research group.<sup>105</sup> It is possible that interaction may be strongly context dependent and pathological transformed lines may have additional, or conversely lack, compensatory mechanisms for TERT-BRG1 interactions. On the other hand, multiple groups have indicated possible TERT interaction with  $\beta$ -catenin in both humans and mice<sup>87,105,115</sup> and the ability to activate resting hair and epithelial stem cells lends credence to an *in vivo* interaction possibly involving  $\beta$ -catenin.<sup>87,90</sup> Since even catalytically inactive TERT is able to enhance iPSC reprogramming<sup>63</sup> requiring an mesenchymal-to-epithelial transition (MET), it is initially curious that the TERT- $\beta$ -catenin association supports the reverse epithelial-to-mesenchymal transition (EMT) in transformed cells.<sup>115</sup> The upregulation of the EMT inhibitor KLF7 in TERT containing iPSCs<sup>63</sup> and nuclear export of  $\beta$ -catenin by E-cadherin<sup>116</sup> may mitigate this effect. However, recent evidence suggests that early activation of an EMT pathway prior to a delayed EMT event actually enhances reprogramming.<sup>117</sup> Ultimately, the enhancement of iPSC reprogramming may be supported by more than one of TERT's non-canonical effects, such as enhanced proliferation, ROS mitigation, NF- $\kappa$ B interaction in addition to its canonical telomere stabilizing effect.

### TERT and mitochondria

Mitochondrial localization of TERT is extensively documented, however, its role in mitigating ROS (Reactive Oxygen Species), and acting as a *TERC* independent reverse transcriptase are only beginning to be understood.<sup>96-100,118,119</sup> It is difficult to unravel the contributions from non-canonical TERT effects versus telomeric effects. The canonical telomere shortening effects generally occur after extended proliferation, and are mediated by telomeric dysfunction. On the other hand, non-canonical effects of TERT should appear immediately upon knockout. For example, removal of the canonical function of mTERT by *mTERC* knockout leads to mitochondrial dysfunction after iPSC and SCNT reprogramming of cells with short telomeres.<sup>44</sup> However, this mitochondrial dysfunction is likely a p53 mediated effect due to the poorly maintained telomeres. The donor cells came from late-generation *Terc*<sup>-/-</sup> mice (hence short telomeres to begin with) and were allowed to grow/differentiate under telomerase-activity-deficient conditions, which may have led to mitochondrial damage.<sup>44</sup> As there is evidence that most mitochondrial localized TERT may not carry *TERC* at all and instead act as a reverse transcriptase for mitochondrial RNA<sup>103</sup> it would be informative to additionally knockdown mTERT<sup>44</sup> to look for decreased ROS scavenging.

To add to the complexity, TERT is capable of binding alternative RNA's including the RNA component of mitochondrial RNA processing endoribonuclease (*RMRP*), with which it can form dsRNA that is processed into siRNA directed against *RMRP*.<sup>102</sup> *RMRP* is required for development, and aside from its involvement in mitochondrial DNA replication,<sup>120</sup> it is also processed into siRNAs that targets several developmentally relevant genes.<sup>121,122</sup> TERT also appears capable of altering miRNA levels, possibly through a BRG1 associated mechanism,<sup>108</sup> although in rat cardiomyocytes the effect is solely on mature miRNAs and seems likely to be mediated through non-specific effects such as increased ROS.<sup>123</sup> It should be interesting to further investigate if these *RMRP* related effects are present in pluripotent stem cells and whether they are capable of altering cellular differentiation pathways.

Aside from the highlighted telomeric effects, TERT and *TERC* knockouts are not lethal in mice, nor do they result in phenotypic/transcriptional WNT pathway defects<sup>124</sup> or typical *RMRP*-related defects.<sup>124</sup> The extensive homology of TERT across species and in-particular vertebrates, and the ability to make at least one *hTERT*-null pluripotent human line<sup>86</sup> makes it difficult to imagine embryonic lethality in *hTERT*-null humans. On the other hand, as discussed in the previous sections, species differences exist and humans appear to suppress ALT pathways and rely more heavily on *hTERT* during development.<sup>49</sup> Alternatively, it is feasible that extra-telomeric effects may be redundant, appearing in sporadic situations where compensatory mechanisms are absent. As functional redundancy may, on a much larger scale, play a significant role in survival of a species, these effects still warrant a significant amount of attention. Additionally, as TERT has abundant isoforms, most of which are catalytically inactive at telomeres, these extra-telomeric roles may be significant.

### Alternative splice forms of telomerase

Telomerase expression and activity is highly regulated by a number of mechanisms, one of which is alternative splicing.<sup>125-129</sup> Alternative splicing is a method utilized by most mammalian cells to increase the transcriptome and protein diversity for extra means of gene regulation.<sup>130</sup> To date, 22 and 31 unique alternative splice variants of TERT have been identified for human and chicken, respectively.<sup>25,131-134</sup>

The human TERT gene is approximately 42 kb in length and contains 15 introns and 16 exons.<sup>135</sup> In most cases, exons are assembled together by joining of evolutionarily conserved 5'-splice donor and 3'-splice acceptor sequences in introns through long-range RNA interaction.<sup>136</sup> Alternative splicing of TERT is achieved by exon-skipping, intron-retention, and use of alternate splice acceptor sequences,<sup>136</sup> and is regulated by SRSF and hnRNP protein families.<sup>24</sup> However, the mechanism of regulation remains largely unclear. Notably, multiple splicing events can occur simultaneously in a single transcript, resulting in very diverse population of TERT isoforms.<sup>137</sup> In many cases, early splicing events within 5'-region of the transcript will introduce premature termination codons (PTCs) nullifying the effect of splicing 3' to these,<sup>25</sup> causing many protein isoforms to be degenerate and/or targeted for non-sense mediated decay (NMD).<sup>138</sup> TERT has several evolutionarily conserved functional domains. The N-terminal end harbours a mitochondrial targeting sequence (MTS), nuclear localization signals (NLSs), and RNA-interacting domains, while the C-terminal half contains multiple reverse-transcriptase-like (RT-like) motifs.<sup>135,139-145</sup> These critical elements are often disrupted in a majority of TERT isoforms to varying extents.<sup>25</sup> Due to this, no currently identified alternative splice variant of hTERT exhibits reverse-transcriptase activity and only the full-length hTERT (containing all 16 exons) retains catalytic activity.<sup>25</sup> Nevertheless, catalytically inactive isoforms are highly expressed throughout human development in a tissue-specific and development-stage dependent manner.<sup>126,128</sup> Moreover, some hTERT isoforms are constitutively generated independently of the full-length hTERT levels.<sup>24,125,127,128,146</sup> Accumulating evidence points to potential roles of hTERT isoforms in the regulation of telomerase functions.<sup>24,128,147-151</sup>

An early attempt to characterize hTERT revealed two of the best-characterized hTERT isoforms,  $\alpha$ - and  $\beta$ -variants.<sup>131,135</sup> The  $\alpha$ -variant results from a partial in-frame deletion (36bp) of exon 6, leading to the partial loss of RT-motif A. This catalytically inactive form of hTERT is a dominant negative inhibitor of telomerase activity when overexpressed in telomerase positive immortal cells.<sup>137,152</sup> Considering the relatively low transcript abundance of the  $\alpha$ -variant,<sup>146,147,151</sup> the level of inhibition may be insufficient for it to have significant impact on telomere maintenance of indefinitely dividing cells. Shortly after the discovery of the  $\alpha$ -variant, Hisatomi *et al.* discovered a new in-frame splicing event that deletes two RT-motifs, rendering catalytic inactivity.<sup>132</sup> Like the  $\alpha$ -variant, the  $\gamma$ -variant was suggested as a negative regulator of telomerase activity. However,  $\gamma$ -transcript levels, relative to those of  $\alpha$ - and  $\beta$ -variants, are extremely low or nearly undetectable in tested cell types.<sup>132,150</sup> Despite low expression levels, the  $\alpha$ - and  $\gamma$ -variants hold much promise in micro-regulation of non-canonical

TERT functions, as they are both in-frame deletion variants with good structural and sequence homology to full-length TERT.

The  $\beta$ -splice variant results from a 182 bp out-of-frame deletion and the subsequent loss of exons 7 and 8.<sup>131,135</sup> Unlike the  $\alpha$ -deletion, the  $\beta$ -deletion introduces a premature termination codon (PTC) causing it to be truncated and a potential NMD target.<sup>138</sup> However, Listerman *et al.* and our group have recently shown that the  $\beta$ -variant transcript associates with polyribosomes, escapes NMD, and is likely translated.<sup>24,85</sup> Surprisingly, the  $\beta$ -deletion transcript not only survives degradation but is one of the most highly expressed TERT transcripts in various cell types including human embryonic stem cells.<sup>24,128,132,147,151</sup> A recent discovery suggests that the  $\beta$ -variant inhibits telomerase activity by sequestering *TERC*.<sup>24</sup> However, *TERC* is expressed at very high levels in most immortal cell types and is rarely a limiting factor for telomerase activity.<sup>125,134,153,154</sup> Despite the truncation, the  $\beta$ -variant retains the MTS, RNA-interaction sites and NLSs. Its abilities to interact with different RNA species and translocate between different cell compartments<sup>24</sup> are strongly suggestive of possible roles in regulation of RNA-mediated extra-telomeric functions of hTERT. Maida *et al.* was the first group to have detected RdrP activity of full-length TERT and to have characterized catalytically active hTERT as a negative regulator of RMRP via siRNA mediated-knockdown.<sup>102,122</sup> This was later confirmed by work of Mukherjee *et al.* in which they also observed reduced proliferation of human mammary epithelial cells upon shRNA mediated-RMRP knockdown.<sup>155</sup> Since the production of siRNA by TERT-RMRP requires catalytic activity, any catalytically inactive forms of hTERT with an intact RNA-binding domain such as  $\beta$ -variant may inhibit cell proliferation by down-regulating siRNA production. Overexpression of the  $\beta$ -variant in HeLa cells showed its ability to associate with mitochondria, the significance of which is not fully understood.<sup>24</sup> In the same study, overexpressed  $\beta$ -variant exhibited anti-apoptotic effects in cisplatin-treated human breast cancer cells by significantly reducing caspase 3/7 activity. Human TERT overexpression studies have shown that full-length hTERT augments mitochondrial function and maintains the integrity of mitochondria DNA under oxidative stress in a context dependent manner.<sup>156-158</sup> Remarkably, overexpression of dominant-negative mutant TERT abrogated or reversed some of these mitochondrial changes, pointing to a potential counter-regulatory role of hTERT alternative splice variants against full-length hTERT in regulating mitochondrial function.<sup>158</sup> This putative interplay between hTERT isoforms hold much significance in settings such as embryonic stem cells where mitochondria (and metabolism) likely play critical roles in governing the stress response, cell fate decisions, and pluripotency. Known factors that affect hTERT-splicing patterns are TGF- $\beta$ 1 and hypoxia.<sup>159,160</sup>

TGF- $\beta$ 1 in human epidermal cells shifts hTERT splicing patterns toward  $\beta$ -variant transcript at the expense of the full-length transcript,<sup>159</sup> whereas hypoxic conditions causes it to shift in the other direction.<sup>160</sup> TGF- $\beta$ 1 is an important cytokine involved in cell proliferation, stem cell maintenance and differentiation through SMAD signaling.<sup>1,2</sup> In addition, hypoxia increases hESC resistance to spontaneous differentiation and improves cell pluripotency through stabilization of hypoxia-

inducible factors and the expression of their target genes.<sup>161</sup> Together, this data suggests that the preferential shift of the TERT splicing pattern is a highly regulated process, which can promptly respond to extra-cellular stimuli that ultimately affect stem cell identity. Reverse-transcriptase function of mTERT may be dispensable for modulation of Wnt- $\beta$ -catenin signaling and its targeted gene expression.<sup>105</sup> This indicates the likelihood that naturally occurring catalytically inactive TERT isoforms regulate Wnt signaling possibly through disruption and/augmentation of the Brg1-TCF-TERT transcription complex formation.

More recently, a novel hTERT isoform (now termed  $\Delta$ 4-13 variant) was discovered in both telomerase-positive and negative human cells.<sup>25</sup> Remarkably, this in-frame alternatively spliced isoform is probably the most promising candidate to help us discern TERT functions that require catalytic activity from the ones that do not, since the alternative splicing almost cleanly excises the RT-domain while maintaining an open reading frame and sequence homology with its full-length counterpart. Overexpression of this variant in telomerase-negative cell lines enhanced cell proliferation and LiCl-induced Wnt signaling.<sup>25</sup> However, the response was not as strong as that seen in the full-length hTERT overexpression controls, suggesting that the isoform may merely be carrying out a redundant role of its full-length counterpart.

Lastly, four independent alternative splicing events within the 5' region of the transcript result in the partial to complete deletion of exon 2 and introduce early PTCs.<sup>25,134</sup> Exon 2 contains portions of the telomerase essential N-terminal domain and RNA-interaction domain, which are lost, along with the catalytic core, in the process of splicing. Translation of the transcripts harboring exon 2 deletions through the wild-type reading frame would render all other potential splicing events downstream of exon 3 defunct due to the PTCs. Of note, the PTC introduced by exon 2 splicing may be bypassed if translation starts at an alternative start site downstream of the wild-type start codon. However, no evidence exists to confirm such a translation pattern to date. Interestingly, Wither *et al.* showed that exon 2-deletion (termed e2) is a common splice event in primates and that the e2 transcripts are highly abundant.<sup>134</sup> In agreement, our preliminary data indicates that the e2 transcripts are present in hESCs and whose amount varies in cells cultured under different oxygen tensions (Betts, unpublished data). Despite the abundance of e2 transcripts, its translational competency is yet to be investigated. Regardless, its naturally high transcript abundance implies that exon 2-deletion may be a non-functional by-product of TERT regulation by alternative splicing, serving as a powerful switch to control telomerase activity and/or non-canonical functions of TERT.

Lack of consistency in methods of comparing isoform transcript abundance and poor antibody availability for TERT and its variants have greatly limited the progress of characterizing alternate splice isoforms of TERT in various species. Nonetheless, newly emerging pieces of evidence indicating the extra-telomeric roles of TERT (Fig. 1) and cell-type specific biases in splicing patterns are supportive of the functional importance of TERT and its variants in pluripotent stem cells. Fig. 1 may be

much more complex with additional isoform specific functions, as well as multiple isoforms modulating each of its current roles.

## Conclusion

Once regarded as a unipartite protein whose sole purpose is to re-lengthen telomeres, TERT is now considered a multi-functional protein, capable of modulating functions beyond telomere maintenance in various cell compartments. It is well accepted that TERT is upregulated in pluripotent stem cells, presumably to support the indefinite cell self-renewal by maintaining telomere lengths. Yet, this understanding lacks appreciation of TERT's possible contribution to pluripotency through its cross talk with the pluripotency network and non-canonical roles. The non-canonical roles of TERT as an active regulator of major signaling pathways, histone modulation, and mitochondrial function have been characterized mostly in a non-PSC context and in different species, making it challenging to gauge the true significance of TERT in PSCs based on our current knowledge of the field. Nonetheless, these functions of TERT, including telomere maintenance, closely relate to a number of highly regulated cell mechanisms of PSCs such as epigenetic and metabolic modulation. Here, we propose ways by which TERT may govern pluripotency and self-renewal in pluripotent stem cells. TERT's canonical and non-canonical functions collectively have a significant impact on pluripotency and self-renewal in pluripotent stem cells.

## Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

## Acknowledgments

The authors thank Dr. Andrew J. Watson and Nicole Edwards for their careful review of the manuscript.

## Funding

This research is supported by operating grants to D.H.B. from the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), and the Children's Health Research Institute (CHRI).

## References

- Muller HJ. The Remaking of Chromosomes. *Collecting Net - Woods Hole* 1938; 13:181-98
- McClintock B. The stability of broken ends of chromosomes in *Zea mays*. *Genetics* 1941; 26:234-82; PMID:17247004
- Chan SR, Blackburn EH. Telomeres and telomerase. *Philos Trans R Soc Lond B Biol Sci* 2004; 359:109-21; PMID:15065663; <http://dx.doi.org/10.1098/rstb.2003.1370>
- Hayflick L. The Limited in Vitro Lifetime of Human Diploid Cell Strains. *Exp Cell Res* 1965; 37:614-36; PMID:14315085; [http://dx.doi.org/10.1016/0014-4827\(65\)90211-9](http://dx.doi.org/10.1016/0014-4827(65)90211-9)
- Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. *Exp Cell Res* 1961; 25:585-621; PMID:13905658; [http://dx.doi.org/10.1016/0014-4827\(61\)90192-6](http://dx.doi.org/10.1016/0014-4827(61)90192-6)
- Armanios M. Telomerase and idiopathic pulmonary fibrosis. *Mutat Res* 2012; 730:52-58; <http://dx.doi.org/10.1016/j.mrfmmm.2011.10.013>
- Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, et al. Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine* 2007; 356:1317-26; PMID:17392301; <http://dx.doi.org/10.1056/NEJMoa066157>
- Aviv A. Genetics of leukocyte telomere length and its role in atherosclerosis. *Mutat Res* 2012; 730:68-74; <http://dx.doi.org/10.1016/j.mrfmmm.2011.05.001>
- Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanoock SJ, Lansdorp PM, Young NS. Mutations in TERT, the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia. *New England Journal of Medicine* 2005; 352:1413-24; PMID:15814878; <http://dx.doi.org/10.1056/NEJMoa042980>
- Carulli L, Anzivino C. Telomere and telomerase in chronic liver disease and hepatocarcinoma. *World Journal of Gastroenterology* : WJG 2014; 20:6287-92; PMID:24876749; <http://dx.doi.org/10.3748/wjg.v20.i20.6287>
- Biron-Shental T, Sukenik-Halevy R, Sharon Y, Goldberg-Bittman L, Kidron D, Fejgin MD, Amiel A. Short telomeres may play a role in placental dysfunction in preeclampsia and intrauterine growth restriction. *American journal of obstetrics and gynecology* 2010; 202:381-e1; PMID:20350645; <http://dx.doi.org/10.1016/j.ajog.2010.01.036>
- Biron-Shental T, Sukenik Halevy R, Goldberg-Bittman L, Kidron D, Fejgin MD, Amiel A. Telomeres are shorter in placental trophoblasts of pregnancies complicated with intrauterine growth restriction (IUGR). *Early human development* 2010; 86:451-6; PMID:20619976; <http://dx.doi.org/10.1016/j.earlhumdev.2010.06.002>
- Biron-Shental T, Kidron D, Sukenik-Halevy R, Goldberg-Bittman L, Sharony R, Fejgin MD, Amiel A. TERC telomerase subunit gene copy number in placentas from pregnancies complicated with intrauterine growth restriction. *Early human development* 2011; 87:73-5; PMID:21168289; <http://dx.doi.org/10.1016/j.earlhumdev.2010.08.024>
- Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in *Tetrahymena* extracts. *Cell* 1985; 43:405-13; PMID:3907856; [http://dx.doi.org/10.1016/0092-8674\(85\)90170-9](http://dx.doi.org/10.1016/0092-8674(85)90170-9)
- Blackburn EH, Collins K. Telomerase: an RNP enzyme synthesizes DNA. *Cold Spring Harb Perspect Biol* 2011; 3:a003558; PMID:20660025; <http://dx.doi.org/10.1101/cshperspect.a003558>
- Artandi SE, DePinho RA. Telomeres and telomerase in cancer. *Carcinogenesis* 2010; 31:9-18; PMID:19887512; <http://dx.doi.org/10.1093/carcin/bgp268>
- Autexier C, Greider CW. Telomerase and cancer: revisiting the telomere hypothesis. *Trends Biochem Sci* 1996; 21:387-91; PMID:8918193; [http://dx.doi.org/10.1016/S0968-0004\(96\)10042-6](http://dx.doi.org/10.1016/S0968-0004(96)10042-6)
- Xie X, Hiona A, Lee AS, Cao F, Huang M, Li Z, Cherry A, Pei X, Wu JC. Effects of long-term culture on human embryonic stem cell aging. *Stem Cells Dev* 2010; 20:127-38; PMID:20629482; <http://dx.doi.org/10.1089/scd.2009.0475>
- Huang Y, Liang P, Liu D, Huang J, Songyang Z. Telomere regulation in pluripotent stem cells. *Protein Cell* 2014; 5:194-202; PMID:24563217; <http://dx.doi.org/10.1007/s13238-014-0028-1>
- Kalmbach K, Robinson LG, Jr, Wang F, Liu L, Keefe D. Telomere length reprogramming in embryos and stem cells. *Biomed Res Int* 2014; 2014:925121; PMID:24719895; <http://dx.doi.org/10.1155/2014/925121>
- Gourronc FA, Klingelutz AJ. Therapeutic opportunities: Telomere maintenance in inducible pluripotent stem cells. *Mutat Res* 2012 730:98-105; PMID:21605571; <http://dx.doi.org/10.1016/j.mrfmmm.2011.05.008>
- Huang J, Wang F, Okuka M, Liu N, Ji G, Ye X, Zuo B, Li M, Liang P, Ge WW, et al. Association of telomere length with authentic pluripotency of ES/iPS cells. *Cell Res* 2011; 21:779-92; PMID:21283131; <http://dx.doi.org/10.1038/cr.2011.16>
- Keefe DL, Franco S, Liu L, Trimarchi J, Cao B, Weitzen S, Agarwal S, Blasco MA. Telomere length predicts embryo fragmentation after in



- vitro fertilization in women—toward a telomere theory of reproductive aging in women. *Am J Obstet Gynecol* 2005; 192:1256-60; discussion 1260-1; PMID:15846215; <http://dx.doi.org/10.1016/j.ajog.2005.01.036>
24. Listerman I, Sun J, Gazzaniga FS, Lukas JL, Blackburn EH. The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis. *Cancer Res* 2013; 73:2817-28; PMID:23610451; <http://dx.doi.org/10.1158/0008-5472.CAN-12-3082>
  25. Hrdlickova R, Nehyba J, Bose HR, Jr. Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation. *Mol Cell Biol* 2012; 32:4283-96; PMID:22907755; <http://dx.doi.org/10.1128/MCB.00550-12>
  26. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB. Telomere length predicts replicative capacity of human fibroblasts. *Proc Natl Acad Sci U S A* 1992; 89:10114-8; PMID:1438199; <http://dx.doi.org/10.1073/pnas.89.21.10114>
  27. Amit M, Carpenter MK, Inokuma MS, Chiu CP, Harris CP, Waknitz MA, Itskovitz-Eldor J, Thomson JA. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. *Dev Biol* 2000; 227:271-278; PMID:11071754; <http://dx.doi.org/10.1006/dbio.2000.9912>
  28. Vaziri H, Chapman KB, Guigova A, Teichroeb J, Lacher MD, Sternberg H, Singec I, Briggs L, Wheeler J, Sampathkumar J, et al. Spontaneous reversal of the developmental aging of normal human cells following transcriptional reprogramming. *Regenerative Medicine* 2010; 5:345-63; PMID:20230312; <http://dx.doi.org/10.2217/rme.10.21>
  29. Winkler T, Hong SG, Decker JE, Morgan MJ, Wu C, Hughes WM 5th, Yang Y, Wangsa D, Padilla-Nash HM, Ried T, et al. Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs. *J Clin Invest* 2013; 123:1952-63; <http://dx.doi.org/10.1172/JCI67146>
  30. Suhr ST, Chang EA, Rodriguez RM, Wang K, Ross PJ, Beyhan Z, Murthy S, Cibelli JB. Telomere dynamics in human cells reprogrammed to pluripotency. *PLoS ONE* 2009; 4:e8124; PMID:19956585; <http://dx.doi.org/10.1371/journal.pone.0008124>
  31. Ji G, Ruan W, Liu K, Wang F, Sakellariou D, Chen J, Yang Y, Okuka M, Han J, Liu Z, et al. Telomere reprogramming and maintenance in porcine iPSCs. *PLoS ONE* 2013; 8:e74202; PMID:24098638; <http://dx.doi.org/10.1371/annotation/f5e4554b-18cc-46ef-ac39-73ac4d6750ae>
  32. Mathew R, Jia W, Sharma A, Zhao Y, Clarke LE, Cheng X, Wang H, Salli U, Vrana KE, Robertson GP, et al. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. *FASEB J* 2010; 24:2702-15; PMID:20354136; <http://dx.doi.org/10.1096/fj.09-148973>
  33. Wang F, Yin Y, Ye X, Liu K, Zhu H, Wang L, Chiourea M, Okuka M, Ji G, Dan J, et al. Molecular insights into the heterogeneity of telomere reprogramming in induced pluripotent stem cells. *Cell Res* 2012; 22:757-68; PMID:22184006; <http://dx.doi.org/10.1038/cr.2011.201>
  34. Yehezkel S, Rebibo-Sabbah A, Segev Y, Tzukerman M, Shaked R, Huber I, Gepstein L, Skorecki K, Selig S. Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives. *Epigenetics* 2011; 6:63-75; PMID:20861676; <http://dx.doi.org/10.4161/epi.6.1.13390>
  35. Park KD, Seong SK, Park YM, Choi Y, Park JH, Lee SH, Baek DH, Kang JW, Choi KS, Park SN, et al. Telomerase reverse transcriptase related with telomerase activity regulates tumorigenic potential of mouse embryonic stem cells. *Stem Cells Dev* 2010; 20:149-57; PMID:20486780; <http://dx.doi.org/10.1089/scd.2009.0523>
  36. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. *Mol Cell Biol* 1996; 16:2932-9; PMID:8649404; <http://dx.doi.org/10.1128/MCB.16.6.2932>
  37. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. *Dev Genet* 1996; 18:173-9; PMID:8934879; [http://dx.doi.org/10.1002/\(SICI\)1520-6408\(1996\)18:2%3c173::AID-DVG10%3e3.0.CO;2-3](http://dx.doi.org/10.1002/(SICI)1520-6408(1996)18:2%3c173::AID-DVG10%3e3.0.CO;2-3)
  38. Zhao Y, Sfeir AJ, Zou Y, Buseman CM, Chow TT, Shay JW, Wright WE. Telomere extension occurs at most chromosome ends and is uncoupled from fill-in in human cancer cells. *Cell* 2009; 138:463-75; PMID:19665970; <http://dx.doi.org/10.1016/j.cell.2009.05.026>
  39. Lapasset L, Milhavel O, Prieur A, Besnard E, Babled A, Ait-Hamou N, Leschik J, Pellestor F, Ramirez JM, De Vos J, et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. *Gen Dev* 2011; 25:2248-53; PMID:22056670; <http://dx.doi.org/10.1101/gad.173922.111>
  40. Agarwal S, Loh YH, McLoughlin EM, Huang J, Park IH, Miller JD, Huo H, Okuka M, Dos Reis RM, Loewer S, et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. *Nature* 2010; 464:292-6; PMID:20164838; <http://dx.doi.org/10.1038/nature08792>
  41. Hemann MT, Strong MA, Hao L-Y, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. *Cell* 107:67-77; PMID:11595186; [http://dx.doi.org/10.1016/S0092-8674\(01\)00504-9](http://dx.doi.org/10.1016/S0092-8674(01)00504-9)
  42. Batista LFZ, Pech MF, Zhong FL, Nguyen HN, Xie KT, Zaugg AJ, Crary SM, Choi J, Sebastiano V, Cherry A, et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. *Nature* 2011; 474:399-402; PMID:21602826; <http://dx.doi.org/10.1038/nature10084>
  43. Huang J, Wang F, Okuka M, Liu N, Ji G, Ye X, Zuo B, Li M, Liang P, Ge WW, et al. Association of telomere length with authentic pluripotency of ES/iPS cells. *Cell Res* 2011; 21:779-92; PMID:21283131; <http://dx.doi.org/10.1038/cr.2011.16>
  44. Le R, Kou Z, Jiang Y, Li M, Huang B, Liu W, Li H, Kou X, He W, Rudolph KL, et al. Enhanced telomere rejuvenation in pluripotent cells reprogrammed via nuclear transfer relative to induced pluripotent stem cells. *Cell Stem Cell* 2014; 14:27-39; PMID:24268696; <http://dx.doi.org/10.1016/j.stem.2013.11.005>
  45. Pucci F, Gardano L, Harrington L. Short Telomeres in ESCs Lead to Unstable Differentiation. *Cell Stem Cell* 2013; 12:479-86; PMID:23561444; <http://dx.doi.org/10.1016/j.stem.2013.01.018>
  46. Dang-Nguyen TQ, Haraguchi S, Furusawa T, Somfai T, Kaneda M, Watanabe S, Akagi S, Kikuchi K, Tajima A, Nagai T. Downregulation of histone methyltransferase genes SUV39H1 and SUV39H2 increases telomere length in embryonic stem-like cells and embryonic fibroblasts in pigs. *J Reprod Dev* 2013; 59:27-32; PMID:23018532
  47. De Bonis ML, Ortega S, Blasco MA. SIRT1 is necessary for proficient telomere elongation and genomic stability of induced pluripotent stem cells. *Stem cell reports* 2014; 2:690-706; PMID:24936455; <http://dx.doi.org/10.1016/j.stemcr.2014.03.002>
  48. Tsai C-C, Chen CL, Liu HC, Lee YT, Wang HW, Hou LT, Hung SC. Overexpression of hTERT increases stem-like properties and decreases spontaneous differentiation in human mesenchymal stem cell lines. *J Biomed Sci* 2010; 17:10-1186; PMID:20152059; <http://dx.doi.org/10.1186/1423-0127-17-10>
  49. Zeng S, Liu L, Sun Y, Xie P, Hu L, Yuan D, Chen D, Ouyang Q, Lin G, Lu G. Telomerase-mediated telomere elongation from human blastocysts to embryonic stem cells. *J Cell Sci* 2014; 127:752-62; PMID:24338368; <http://dx.doi.org/10.1242/jcs.131433>
  50. Liu L, Bailey SM, Okuka M, Muñoz P, Li C, Zhou L, Wu C, Czerwiec E, Sandler L, Seyfang A, et al. Telomere lengthening early in development. *Nat Cell Biol* 2007; 9:1436-41; PMID:17982445; <http://dx.doi.org/10.1038/ncb1664>
  51. Zalzman M, Falco G, Sharova LV, Nishiyama A, Thomas M, Lee SL, Stagg CA, Hoang HG, Yang HT, Indig FE, et al. Zscan4 regulates telomere elongation and genomic stability in ES cells. *Nature* 2010; 464:858-63; PMID:20336070; <http://dx.doi.org/10.1038/nature08882>
  52. Varela E, Schneider RP, Ortega S, Blasco MA. Different telomere-length dynamics at the inner cell mass versus established embryonic stem (ES) cells. *Proc Natl Acad Sci* 2011; 108(37):15207-12; PMID:21873233
  53. Marion RM, Strati K, Li H, Tejera A, Schoeffner S, Ortega S, Serrano M, Blasco MA. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. *Cell Stem Cell* 2009; 4:141-54; PMID:19200803; <http://dx.doi.org/10.1016/j.stem.2008.12.010>
  54. Jiang J, Lv W, Ye X, Wang L, Zhang M, Yang H, Okuka M, Zhou C, Zhang X, Liu L, et al. Zscan4 promotes genomic stability during

- reprogramming and dramatically improves the quality of iPSC cells as demonstrated by tetraploid complementation. *Cell research* 2013; 23:92-106; PMID:23147797; <http://dx.doi.org/10.1038/cr.2012.157>
55. Lee K, Gollahon, L. Abstract 2047: The interaction of ZSCAN4 with TRF1: Effects on regulation of telomere elongation in cancer cells. *Cancer research* 2012; 72:2047; PMID:26403970; <http://dx.doi.org/10.1158/1538-7445.AM2012-2047>
  56. Dan J, Liu Y, Liu N, Chiourea M, Okuka M, Wu T, Ye X, Mou C, Wang L, Wang L, et al. Rif1 maintains telomere length homeostasis of ESCs by mediating heterochromatin silencing. *Developmental cell* 2014; 29:7-19; PMID:24735877; <http://dx.doi.org/10.1016/j.devcel.2014.03.004>
  57. Schneider RP, Garrobo I, Foronda M, Palacios JA, Marión RM, Flores I, Ortega S, Blasco MA. TRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells. *Nature communications* 2013; 4:1946; PMID: 23735977
  58. Ozturk S, Sozen B, Demir N. Telomere length and telomerase activity during oocyte maturation and early embryo development in mammalian species. *Molecular human reproduction* 2014; 20:15-30; PMID:23928157; <http://dx.doi.org/10.1093/molehr/gat055>
  59. Blasco MA. Telomere length, stem cells and aging. *Nature chemical biology* 2007; 3:640-649; PMID:17876321; <http://dx.doi.org/10.1038/nchembio.2007.38>
  60. Wong LH, Ren H, Williams E, McGhie J, Ahn S, Sim M, Tam A, Earle E, Anderson MA, Mann J, et al. Histone H3.3 incorporation provides a unique and functionally essential telomeric chromatin in embryonic stem cells. *Genome research* 2009; 19:404-14; PMID:19196724; <http://dx.doi.org/10.1101/gr.084947.108>
  61. Zhou Y, Zhou P, Xin Y, Wang J, Zhu Z, Hu J, Wei S, Ma H. Trend of telomerase activity change during human iPSC self-renewal and differentiation revealed by a quartz crystal microbalance based assay. *Sci Rep* 2014; 4:6978; PMID:25381797; <http://dx.doi.org/10.1038/srep06978>
  62. Dashnimaev EB, et al. Induction of telomerase activity increase reprogramming efficiency of human dermal fibroblasts. *Moscow University Biological Sciences Bulletin* 2012; 67:6-12; <http://dx.doi.org/10.3103/S0096392512010038>
  63. Kinoshita T, Nagamatsu G, Saito S, Takubo K, Horimoto K, Suda T. Telomerase Reverse Transcriptase Has an Extratelomeric Function in Somatic Cell Reprogramming. *Journal of Biological Chemistry* 2014; 289:15776-87; PMID:24733392; <http://dx.doi.org/10.1074/jbc.M113.536037>
  64. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. Defining Molecular Cornerstones during Fibroblast to iPSC Cell Reprogramming in Mouse. *Cell Stem Cell* 2008;2:230-40; PMID:18371448; <http://dx.doi.org/10.1016/j.stem.2008.02.001>
  65. Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R, Kemler R. Wnt/ $\beta$ -Catenin Signaling Regulates Telomerase in Stem Cells and Cancer Cells. *Science* 2012; 336:1549-54; PMID:22723415; <http://dx.doi.org/10.1126/science.1218370>
  66. Wong C-W, Hou PS, Tseng SF, Chien CL, Wu KJ, Chen HF, Ho HN, Kyo S, Teng SC. Krüppel-Like Transcription Factor 4 Contributes to Maintenance of Telomerase Activity in Stem Cells. *Stem Cells* 2010; 28:1510-17; PMID:20629177; <http://dx.doi.org/10.1002/stem.477>
  67. Zhang Y, Toh L, Lau P, Wang X. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/ $\beta$ -catenin pathway in human cancer. *Journal of Biological Chemistry* 2012; 287:32494-511; PMID:22854964; <http://dx.doi.org/10.1074/jbc.M112.368282>
  68. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. A p53-mediated DNA damage response limits reprogramming to ensure iPSC cell genomic integrity. *Nature* 2009; 460:1149-53; PMID:19668189; <http://dx.doi.org/10.1038/nature08287>
  69. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. *Nat Cell Biol* 2005; 7:1074-82; PMID:16244670; <http://dx.doi.org/10.1038/ncb1314>
  70. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell* 2006;126:663-76; PMID:16904174; <http://dx.doi.org/10.1016/j.cell.2006.07.024>
  71. Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc Is Dispensable for Direct Reprogramming of Mouse Fibroblasts. *Cell Stem Cell* 2:10-12; PMID:18371415; <http://dx.doi.org/10.1016/j.stem.2007.12.001>
  72. Wu K-J, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R. Direct activation of TERT transcription by c-MYC. *Nat Genet* 1999; 21:220-4; PMID:9988278; <http://dx.doi.org/10.1038/6010>
  73. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. *Gen Dev* 1998; 12:1769-74; PMID:9637678; <http://dx.doi.org/10.1101/gad.12.12.1769>
  74. Bourillot PY, Aksoy I, Schreiber V, Wianny F, Schulz H, Hummel O, Hubner N, Savatier P. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. *Stem Cells* 2009; 27:1760-71; PMID:19544440; <http://dx.doi.org/10.1002/stem.110>
  75. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells. *Cell* 137:647-58; PMID:19409607; <http://dx.doi.org/10.1016/j.cell.2009.02.038>
  76. Erdmann N, Liu Y, Harrington L. Distinct dosage requirements for the maintenance of long and short telomeres in mTert heterozygous mice. *Proc Natl Acad Sci of the United States of America* 2004; 101:6080-5; PMID:15079066; <http://dx.doi.org/10.1073/pnas.0401580101>
  77. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, Greider CW. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. *Cell* 1997; 91:25-34; PMID:9335332; [http://dx.doi.org/10.1016/S0092-8674\(01\)80006-4](http://dx.doi.org/10.1016/S0092-8674(01)80006-4)
  78. Sung L-Y, Chang WF, Zhang Q, Liu CC, Liou JY, Chang CC, Ouyang H, Guo R, Fu H, Cheng WT, et al. Telomere Elongation and Naive Pluripotent Stem Cells Achieved from Telomerase Haplo-Insufficient Cells by Somatic Cell Nuclear Transfer. *Cell reports* 2014; 9:1603-9; PMID:25464850; <http://dx.doi.org/10.1016/j.celrep.2014.10.052>
  79. Feng B, Jiang J, Kraus P, Ng JH, Heng JC, Chan YS, Yaw LP, Zhang W, Loh YH, Han J, et al. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. *Nat Cell Biol* 2009; 11:197-203; PMID:19136965; <http://dx.doi.org/10.1038/ncb1827>
  80. Festuccia N, Osorno R, Halbritter F, Karwacki-Neisius V, Navarro P, Colby D, Wong F, Yates A, Tomlinson SR, Chambers I. Esrrb is a direct nanog target gene that can substitute for nanog function in pluripotent cells. *Cell Stem Cell* 2012; 11:477-90; PMID:23040477; <http://dx.doi.org/10.1016/j.stem.2012.08.002>
  81. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct Regulatory Mechanisms and Functions for p53-Activated and p53-Repressed DNA Damage Response Genes in Embryonic Stem Cells. *Molecular Cell* 2012; 46:30-42; PMID:22387025; <http://dx.doi.org/10.1016/j.molcel.2012.01.020>
  82. Li L, Wang S, Jezierski A, Moalim-Nour L, Mohib K, Parks RJ, Retta SF, Wang L. A unique interplay between Rap1 and E-cadherin in the endocytic pathway regulates self-renewal of human embryonic stem cells. *Stem Cells* 2010; 28:247-57; PMID:20039365; <http://dx.doi.org/10.1002/stem.532>
  83. Fong YW, Ho JJ, Inouye C, Tjian R. The dyskerin ribonucleoprotein complex as an OCT4/SOX2 coactivator in embryonic stem cells (ed. Blencowe, BJ.) *Elife* 3; e03573 (2014); PMID:25407680
  84. Yang C, Przyborski S, Cooke MJ, Zhang X, Stewart R, Anyfantis G, Atkinson SP, Saretzki G, Armstrong L, et al. A key role for telomerase reverse transcriptase unit in modulating human embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. *Stem Cells* 2008; 26:850-63; PMID:18203676; <http://dx.doi.org/10.1634/stemcells.2007-0677>
  85. Radan L, Hughes CS, Teichroeb JH, Vieira Zamora FM, Jewer M, Postovit LM, Betts DH. Microenvironmental regulation of telomerase isoforms in human embryonic stem cells. *Stem Cells Dev* 2014; 23:2046-66; PMID:24749509; <http://dx.doi.org/10.1089/scd.2013.0373>
  86. Sexton AN, Regalado SG, Lai CS, Cost GJ, O'Neil CM, Urnov FD, Gregory PD, Jaenisch R, Collins K, Hockemeyer D. Genetic and

- molecular identification of three human TPP1 functions in telomerase action: recruitment, activation, and homeostasis set point regulation. *Gen Dev* 2014; 28:1885-99; PMID:25128433; <http://dx.doi.org/10.1101/gad.246819.114>
87. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, Cheung P, Jun S, Artandi MK, Shah N, et al. TERT Promotes Epithelial Proliferation through Transcriptional Control of a Myc- and Wnt-Related Developmental Program. *PLoS Genet* 2008; 4:e10; PMID:18208333; <http://dx.doi.org/10.1371/journal.pgen.0040010>
  88. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. *Cell Res* 2008; 18:725-32; PMID:18574498; <http://dx.doi.org/10.1038/cr.2008.74>
  89. Gu B-W, Bessler M, Mason PJ. A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. *Proc Natl Acad Sci* 2008; 105:10173-8; PMID:18626023; <http://dx.doi.org/10.1073/pnas.0803559105>
  90. Sarin KY. Conditional telomerase induction causes proliferation of hair follicle stem cells. *Nature* 2005; 436:1048-52; PMID:16107853; <http://dx.doi.org/10.1038/nature03836>
  91. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. *Proc Natl Acad Sci* 2002; 99:12606-11; PMID:12193655; <http://dx.doi.org/10.1073/pnas.182407599>
  92. Smith LL, Collier HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. *Nat Cell Biol* 2003; 5:474-9; PMID:12717449; <http://dx.doi.org/10.1038/ncb985>
  93. Flores I, Cayuela ML, Blasco MA. Effects of Telomerase and Telomere Length on Epidermal Stem Cell Behavior. *Science* 2005; 309:1253-6; PMID:16037417; <http://dx.doi.org/10.1126/science.1115025>
  94. Martínez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. *Nat Rev Cancer* 2011; 11:161-76; PMID:21346783; <http://dx.doi.org/10.1038/nrc3025>
  95. Blasco MA. Telomerase beyond telomeres. *Nat Rev Cancer* 2002; 2:627-33; PMID:12154355; <http://dx.doi.org/10.1038/nrc862>
  96. Singhapol C, Pal D, Czapiewski R, Porika M, Nelson G, Saretzki GC. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. *PLoS ONE* 2013; 8:9; PMID:23326372; <http://dx.doi.org/10.1371/journal.pone.0052989>
  97. Indran IR, Hande MP, Pervaiz S. hTERT Overexpression Alleviates Intracellular ROS Production, Improves Mitochondrial Function, and Inhibits ROS-Mediated Apoptosis in Cancer Cells. *Cancer Res* 2011; 71:266-76; PMID:21071633; <http://dx.doi.org/10.1158/0008-5472.CAN-10-1588>
  98. Nitta E, Yamashita M, Hosokawa K, Xian M, Takubo K, Arai F, Nakada S, Suda T. Telomerase reverse transcriptase protects ATM-deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere-independent mechanism 2011.
  99. Liu Z, Wan P, Duan H, Zhou J, Tan B, Liu Y, Zhou Q, Zhou C, Huang Z, Tian B, et al. ES micro-environment enhances stemness and inhibits apoptosis in human limbal stem cells via the maintenance of telomerase activity. *PLoS ONE* 2013; 8:e53576; PMID:23326460; <http://dx.doi.org/10.1371/journal.pone.0053576>
  100. Mattiussi M, Tilman G, Lenglez S, Decottignies A. Human telomerase represses ROS-dependent cellular responses to Tumor Necrosis Factor- $\alpha$  without affecting NF- $\kappa$ B activation. *Cellular Signalling* 2012; 24:708-17; PMID:22108091; <http://dx.doi.org/10.1016/j.celsig.2011.11.004>
  101. Kong F, Zheng C, Xu D. Telomerase as a "stemness" enzyme. *Science China Life Sciences* 2014; 57:564-70; PMID:24829107; <http://dx.doi.org/10.1007/s11427-014-4666-6>
  102. Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. *Nature* 2009; 461:230-5; PMID:19701182; <http://dx.doi.org/10.1038/nature08283>
  103. Sharma NK, Reyes A, Green P, Caron MJ, Bonini MG, Gordon DM, Holt IJ, Santos JH. Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. *Nucleic Acids Res* 2011; 40:712-25; PMID:21937513
  104. Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R, Shibata T, Ligon KL, Fukami K, Hahn WC, et al. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. *Proc Natl Acad Sci U S A* 2011; 108:20388-93; PMID:21730156; <http://dx.doi.org/10.1073/pnas.1015171108>
  105. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. *Nature* 2009; 460:66-72; PMID:19571879; <http://dx.doi.org/10.1038/nature08137>
  106. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, Wong M, Zhang Z, Li G, Sung WK, et al. Telomerase directly regulates NF- $\kappa$ B-dependent transcription. *Nat Cell Biol* 2012; 14:1270-1281; PMID:23159929; <http://dx.doi.org/10.1038/ncb2621>
  107. Maida Y, Yasukawa M, Okamoto N, Ohka S, Kinoshita K, Totoki Y, Ito TK, Minamino T, Nakamura H, Yamaguchi S, et al. Involvement of telomerase reverse transcriptase in heterochromatin maintenance. *Mol Cell Biol* 2014; 34:1576-93; PMID:24550003; <http://dx.doi.org/10.1128/MCB.00093-14>
  108. Lassmann T, Maida Y, Tomaru Y, Yasukawa M, Ando Y, Kojima M, Kasim V, Simon C, Daub CO, Carninci P, et al. Telomerase Reverse Transcriptase Regulates microRNAs. *Int J Mol Sci* 2015; 16:1192-208; PMID:25569094; <http://dx.doi.org/10.3390/ijms16011192>
  109. Hang CT, Yang J, Han P, Cheng HL, Shang C, Ashley E, Zhou B, Chang CP. Chromatin regulation by Brg1 underlies heart muscle development and disease. *Nature* 2010; 466:62-67; PMID:20596014; <http://dx.doi.org/10.1038/nature09130>
  110. Griffin CT, Brennan J, Magnuson T. The chromatin-remodeling enzyme BRG1 plays an essential role in primitive erythropoiesis and vascular development. *Development* 2008; 135:493-500; PMID:18094026; <http://dx.doi.org/10.1242/dev.010090>
  111. Seo S, Richardson GA, Kroll KL. The SWI/SNF chromatin remodeling protein Brg1 is required for vertebrate neurogenesis and mediates transactivation of Ngn and NeuroD. *Development* 2005; 132:105-15; PMID:15576411; <http://dx.doi.org/10.1242/dev.01548>
  112. Bultman S, Gebuhr T, Yee D, La Mantia C, Nicholson J, Gilliam A, Randazzo F, Metzger D, Chambon P, Crabtree G, et al. A Brg1 Null Mutation in the Mouse Reveals Functional Differences among Mammalian SWI/SNF Complexes. *Mol Cell* 2000; 6:1287-95; PMID:11163203; [http://dx.doi.org/10.1016/S1097-2765\(00\)00127-1](http://dx.doi.org/10.1016/S1097-2765(00)00127-1)
  113. Bultman SJ, Gebuhr TC, Pan H, Svoboda P, Schultz RM, Magnuson T. Maternal BRG1 regulates zygotic genome activation in the mouse. *Gen Dev* 2006; 20:1744-54; PMID:16818606; <http://dx.doi.org/10.1101/gad.1435106>
  114. Listerman I, Gazzaniga FS, Blackburn EH. An investigation of the effects of the core protein telomerase reverse transcriptase on wnt signaling in breast Cancer cells. *Mol Cell Biol* 2014; 34:280-9; PMID:24216762; <http://dx.doi.org/10.1128/MCB.00844-13>
  115. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Björkholm M, et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. *Oncogene* 2013; 32:4203-13; PMID:23045275; <http://dx.doi.org/10.1038/onc.2012.441>
  116. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. *J Cell Sci* 1999; 112 (Pt 8), 1237-45; PMID:10085258
  117. Liu X, Sun H, Qi J, Wang L, He S, Liu J, Feng C, Chen C, Li W, Guo Y, et al. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. *Nat Cell Biol* 2013; 15:829-38; PMID:23708003; <http://dx.doi.org/10.1038/ncb2765>
  118. Moselehi J, DePinho RA, Sahin E. Telomeres and Mitochondria in the Aging Heart. *Circulation Res* 2012; 110:1226-37; PMID:22539756; <http://dx.doi.org/10.1161/CIRCRESAHA.111.246868>
  119. Saretzki G. Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress. *Curr Pharmaceutical Design*

- 2014; 20:6386-403; PMID:24975608; <http://dx.doi.org/10.2174/1381612820666140630095606>
120. Chang DD, Clayton DA. A novel endoribonuclease cleaves at a priming site of mouse mitochondrial DNA replication. *The EMBO Journal* 1987; 6:409-17; PMID:3582365
  121. Rosenbluh J, Nijhawan D, Chen Z, Wong KK, Masutomi K, Hahn WC. RMRP Is a Non-Coding RNA Essential for Early Murine Development. *PLoS ONE* 2011; 6:e26270; PMID:22039455; <http://dx.doi.org/10.1371/journal.pone.0026270>
  122. Maida Y, Kyo S, Lassmann T, Hayashizaki Y, Masutomi K. Off-Target Effect of Endogenous siRNA Derived from RMRP in Human Cells. *Int J Mol Sci* 2013; 14:9305-18; PMID:23629666; <http://dx.doi.org/10.3390/ijms14059305>
  123. Drevytska TI, Nagibin VS, Gurianova VL, Kedlyan VR, Moibenko AA, Dosenko VE. Silencing of TERT decreases levels of miR-1, miR-21, miR-29a and miR-208a in cardiomyocytes. *Cell Biochem Funct* 2014; 32:565-70; PMID:25156787; <http://dx.doi.org/10.1002/cbf.3051>
  124. Strong MA, Vidal-Cardenas SL, Karim B, Yu H, Guo N, Greider CW. Phenotypes in mTERT(+)(-) and mTERT(-)(-) mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. *Mol Cell Biol* 2011; 31:2369-79; PMID:21464209; <http://dx.doi.org/10.1128/MCB.05312-11>
  125. Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. *Nucleic Acids Res* 2001; 29:4818-25; PMID:11726691; <http://dx.doi.org/10.1093/nar/29.23.4818>
  126. Ulaner GA, Giudice LC. Developmental regulation of telomerase activity in human fetal tissues during gestation. *Mol Hum Reprod* 1997; 3:769-73; PMID:9358002; <http://dx.doi.org/10.1093/molehr/3.9.769>
  127. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. *Cancer Res* 1998; 58:4168-72; PMID:9751630
  128. Ulaner GA, Hu J-F, Vu TH, Giudice LC, Hoffman AR. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. *Int J Cancer* 2001; 91:644-9; PMID:11267974; [http://dx.doi.org/10.1002/1097-0215\(200002\)9999:9999%3c::AID-IJC1103%3e3.0.CO;2-V](http://dx.doi.org/10.1002/1097-0215(200002)9999:9999%3c::AID-IJC1103%3e3.0.CO;2-V)
  129. Yokoyama Y, Wan X, Takahashi Y, Shinohara A, Tamaya T. Alternatively spliced variant deleting exons 7 and 8 of the human telomerase reverse transcriptase gene is dominantly expressed in the uterus. *Mol Hum Reprod* 2001; 7:853-7; PMID:11517292; <http://dx.doi.org/10.1093/molehr/7.9.853>
  130. Graveley BR. Alternative splicing: increasing diversity in the proteomic world. *Trends Genet* 2001; 17:100-7; PMID:11173120; [http://dx.doi.org/10.1016/S0168-9525\(00\)02176-4](http://dx.doi.org/10.1016/S0168-9525(00)02176-4)
  131. Killian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. *Hum Mol Genet* 1997; 6:2011-9; PMID:9328464; <http://dx.doi.org/10.1093/hmg/6.12.2011>
  132. Hisatomi H, Ohyashiki K, Ohyashiki JH, Nagao K, Kanamaru T, Hirata H, Hibi N, Tsukada Y. Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. *Neoplasia* 2003; 5:193-7; PMID:12869302; [http://dx.doi.org/10.1016/S1476-5586\(03\)80051-9](http://dx.doi.org/10.1016/S1476-5586(03)80051-9)
  133. Sæbøe-Larssen S, Fossberg E, Gaudernack G. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. *BMC Mol Biol* 2006; 7:26; PMID: 16939641
  134. Withers JB, Ashvetiya T, Beemon KL. Exclusion of exon 2 is a common mRNA splice variant of primate telomerase reverse transcriptases. *PLoS One* 2012; 7:e48016; PMID:23110161; <http://dx.doi.org/10.1371/journal.pone.0048016>
  135. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). *Gene* 1999; 232:97-106; PMID:10333526; [http://dx.doi.org/10.1016/S0378-1119\(99\)00108-0](http://dx.doi.org/10.1016/S0378-1119(99)00108-0)
  136. Wong Mandy S, Chen L, Foster C, Kainthla R, Shay JW, Wright WE. Regulation of Telomerase Alternative Splicing: A Target for Chemotherapy. *Cell Rep* 2013; 3:1028-35; PMID:23562158; <http://dx.doi.org/10.1016/j.celrep.2013.03.011>
  137. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. *Neoplasia* 2000; 2:433-40; PMID:11191110; <http://dx.doi.org/10.1038/sj.neo.7900113>
  138. Nicholson P, Yepiskoposyan H, Metze S, Zamudio Orozco R, Kleinschmidt N, Mühlemann O. Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. *Cell Mol Life Sci* 2010; 67:677-700; PMID:19859661; <http://dx.doi.org/10.1007/s00018-009-0177-1>
  139. Santos JH, Meyer JN, Skorvaga M, Annab LA, Van Houten, B. Mitochondrial hTERT exacerbates free-radical-mediated mtDNA damage. *Aging Cell* 2004; 3:399-411; PMID:15569357; <http://dx.doi.org/10.1111/j.1474-9728.2004.00124.x>
  140. Chung J, Khadka P, Chung IK. Nuclear import of hTERT requires a bipartite nuclear localization signal and Akt-mediated phosphorylation. *J Cell Sci* 2012; 125:2684-97; PMID:22366458; <http://dx.doi.org/10.1242/jcs.099267>
  141. Xia J, Peng Y, Mian IS, Lue NF. Identification of functionally important domains in the N-terminal region of telomerase reverse transcriptase. *Mol Cell Biol* 2000; 20:5196-207; PMID:10866675; <http://dx.doi.org/10.1128/MCB.20.14.5196-5207.2000>
  142. Seimiya H, Tanji M, Oh-hara T, Tomida A, Naasani I, Tsuruo T. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. *Biochem Biophys Res Commun* 1999; 260:365-70; PMID:10403776; <http://dx.doi.org/10.1006/bbrc.1999.0910>
  143. Haendeler J, Hoffmann J, Brandes RP, Zeiher AM, Dimmeler S. Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of tyrosine 707. *Mol Cell Biol* 2003; 23:4598-610; PMID:12808100; <http://dx.doi.org/10.1128/MCB.23.13.4598-4610.2003>
  144. Arai K, Masutomi K, Khurts S, Kaneko S, Kobayashi K, Murakami S. Two independent regions of human telomerase reverse transcriptase are important for its oligomerization and telomerase activity. *J Biol Chem* 2002; 277:8538-44; PMID:11751869; <http://dx.doi.org/10.1074/jbc.M111068200>
  145. Jakob S, Schroeder P, Lukosz M, Büchner N, Spyridopoulos I, Altschmied J, Haendeler J. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. *J Biol Chem* 2008; 283:33155-61; PMID:18829466; <http://dx.doi.org/10.1074/jbc.M805138200>
  146. Mavrogianou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamani L, Lianidou ES. Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer. *Clin Chem* 2007; 53:53-61; PMID:17130181; <http://dx.doi.org/10.1373/clinchem.2006.073015>
  147. Lincz LF, Mudge LM, Scorgie FE, Sakoff JA, Hamilton CS, Seldon M. Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variant. *Neoplasia* 2008; 10:1131-7; PMID:18813352; <http://dx.doi.org/10.1593/neo.08644>
  148. Ohyashiki JH, Hisatomi H, Nagao K, Honda S, Takaku T, Zhang Y, Sashida G, Ohyashiki K. Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells. *Br J Cancer* 2005; 92:1942-7; PMID:15827550; <http://dx.doi.org/10.1038/sj.bjc.6602546>
  149. Villa R, Porta CD, Folini M, Daidone MG, Zaffaroni N. Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. *J Invest Dermatol* 2001; 116:867-73; PMID:11407973; <http://dx.doi.org/10.1046/j.1523-1747.2001.01343.x>
  150. Liu Y, Wu BQ, Zhong HH, Tian XX, Fang WG. Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer. *PLoS One* 2012; 7:e38868; PMID:22723897; <http://dx.doi.org/10.1371/journal.pone.0038868>

151. Rha SY, Jeung HC, Park KH, Kim JJ, Chung HC. Changes of telomerase activity by alternative splicing of full-length and beta variants of hTERT in breast cancer patients. *Oncol Res* 2009; 18:213-20; PMID:20225759; <http://dx.doi.org/10.3727/096504009X12596189659123>
152. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. *Neoplasia* 2000; 2:426-32; PMID:11191109; <http://dx.doi.org/10.1038/sj.neo.7900112>
153. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. *Science* 2007; 315:1850-3; PMID:17395830; <http://dx.doi.org/10.1126/science.1138596>
154. Yi X, Tesmer VM, Savre-Train I, Shay JW, Wright WE. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. *Mol Cell Biol* 1999; 19:3989-97; PMID:10330139; <http://dx.doi.org/10.1128/MCB.19.6.3989>
155. Mukherjee S, Firpo EJ, Wang Y, Roberts JM. Separation of telomerase functions by reverse genetics. *Proc Natl Acad Sci U S A* 2011; 108:E1363-71; PMID:21949400; <http://dx.doi.org/10.1073/pnas.1112414108>
156. Santos JH, Meyer JN, Van Houten B. Mitochondrial localization of telomerase as a determinant for hydrogen peroxide-induced mitochondrial DNA damage and apoptosis. *Hum Mol Genet* 2006; 15:1757-68; PMID:16613901; <http://dx.doi.org/10.1093/hmg/ddl098>
157. Buchner N, Zschauer TC, Lukosz M, Altschmied J, Haendeler J. Downregulation of mitochondrial telomerase reverse transcriptase induced by H<sub>2</sub>O<sub>2</sub> is Src kinase dependent. *Exp Gerontol* 2010; 45:558-62; PMID:20211239; <http://dx.doi.org/10.1016/j.exger.2010.03.003>
158. Haendeler J, Dröse S, Büchner N, Jakob S, Altschmied J, Goy C, Spyridopoulos I, Zeiher AM, Brandt U, Dimmeler S. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. *Arterioscler Thromb Vasc Biol* 2009; 29:929-35; PMID:19265030; <http://dx.doi.org/10.1161/ATVBAHA.109.185546>
159. Cerezo A, Kalthoff H, Schuermann M, Schafer B, Boukamp P. Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. *J Cell Sci* 2002; 115:1305-12; PMID:11884529
160. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. *Oncogene* 2006; 25:61-9; PMID:16170363
161. Forristal CE, Wright KL, Hanley NA, Oreffo RO, Houghton FD. Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. *Reproduction* 2010; 139:85-97; PMID:19755485; <http://dx.doi.org/10.1530/REP-09-0300>
162. Turner S, Wong HP, Rai J, Hartshorne GM. Telomere lengths in human oocytes, cleavage stage embryos and blastocysts. *Molecular Human Reproduction* 2010; 16:685-694; PMID:20573647; <http://dx.doi.org/10.1093/molehr/gaq048>
163. Akiyama M, Yamada O, Hideshima T, Yanagisawa T, Yokoi K, Fujisawa K, Eto Y, Yamada H, Anderson KC. TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes. *Biochem Biophys Res Commun* 2004; 316:528-32; PMID:15020249; <http://dx.doi.org/10.1016/j.bbrc.2004.02.080>